Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System ( IHS4 ): A post hoc analysis of the SUNSHINE and SUNRISE trials
Journal of the European Academy of Dermatology and Venereology · 2025
DOI: 10.1111/jdv.20369 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Christos C Zouboulis und 15 weiteren Autor:innen. Beteiligte Einrichtung: European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatologic Agents, Hidradenitis Suppurativa, Severity of Illness Index. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis.
Abstract (Originalsprache)
Introduction
The International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool that measures inflammatory lesions, including draining tunnels, in hidradenitis suppurativa (HS).
Objective
To evaluate secukinumab efficacy using IHS4 in patients with moderate to severe HS.
Methods
Data from the SUNSHINE and SUNRISE trials, which assessed subcutaneous secukinumab 300 mg every 2 (SECQ2W) and 4 (SECQ4W) weeks in adults with moderate to severe HS, were analyzed. Assessments included changes from baseline in IHS4 and severity classification up to Week 52; IHS4‐55, IHS4‐75, IHS4‐90 responses (55%, 75% and 90% reduction in IHS4) and concordance between IHS4‐55 and HS clinical response (HiSCR), at Weeks 16 and 52.
Results
In total, 1084 patients (SECQ2W = 361; SECQ4W = 360; placebo = 363) were analyzed. At Week 16, SECQ2W and SECQ4W demonstrated a numerically higher reduction in IHS4 from baseline versus placebo (adjusted mean [95% CI]: −10.80 [−12.30 to −9.30] and −9.46 [−10.96 to −7.96] vs. −4.92 [−6.43 to −3.41]); the reduction was maintained until Week 52 in both dose regimens. A greater proportion of patients achieved IHS4‐55 with SECQ2W (43.4%) and SECQ4W (39.5%) versus placebo (31.5%) at Week 16, with further improvement at Week 52. Similar trends were observed for IHS4‐75 and IHS4‐90 responses. While no patients had mild disease based on IHS4 (80.7% had severe and 19.3% had moderate HS) at baseline, a greater proportion of patients were categorized as having mild disease at Week 16 in the SECQ2W (25.9%) and SECQ4W (24.0%) groups versus placebo (16.4%); this trend continued up to Week 52 in both dose regimens. Strong concordance (>85%) was observed between IHS4‐55 and HiSCR.
Conclusions
Both SECQ2W and SECQ4W demonstrated efficacy in improving treatment response as measured by IHS4 and reducing disease severity versus placebo at Week 16 and these improvements were sustained through Week 52. These findings support that the dynamic and dichotomous IHS4 can efficiently detect treatment response changes in clinical trial settings. Clinical Trials Registration SUNSHINE (NCT03713619); SUNRISE (NCT03713632).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.
- Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
- Department of Maxillofacial Surgery, Papanikolaou General Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Dermatology, Zeeland University Hospital, Roskilde, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Christos C Zouboulis, Athanassios Kyrgidis, Afsaneh Alavi, Angelo V Marzano
Förderung
- Novartis
Zitieren
APA
Zouboulis, C. C., Kyrgidis, A., Alavi, A., Jemec, G. B. E., Martorell, A., Marzano, A. V., van der Zee, H. H., Wozniak, M. B., Martinez, A. L., Kasparek, T., Bachhuber, T., Ortmann, C. E., Lobach, I., Thomas, N., Ravichandran, S., & Tzellos, T. (2025). Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System ( IHS4 ): A post hoc analysis of the SUNSHINE and SUNRISE trials. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20369
Vancouver
Zouboulis CC, Kyrgidis A, Alavi A, Jemec GBE, Martorell A, Marzano AV, et al. Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System ( IHS4 ): A post hoc analysis of the SUNSHINE and SUNRISE trials. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20369
BibTeX
@article{Zouboulis2025,
author = {Zouboulis, Christos C and Kyrgidis, Athanassios and Alavi, Afsaneh and Jemec, Gregor B E and Martorell, Antonio and Marzano, Angelo V and van der Zee, Hessel H and Wozniak, Magdalena B and Martinez, Angela Llobet and Kasparek, Torben and Bachhuber, Teresa and Ortmann, Christine-Elke and Lobach, Iryna and Thomas, Nicolas and Ravichandran, Shoba and Tzellos, Thrasyvoulos},
title = {Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System ( IHS4 ): A post hoc analysis of the SUNSHINE and SUNRISE trials},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
doi = {10.1111/jdv.20369}
}
EUVIMED